FDA OKs GSK’s Tykerb for HER2-Positive Breast Cancer; GSK to Expand Drug to Other Cancer Populations
GlaxoSmithKline announced this week that the United States Food and Drug Administration has approved Tykerb (lapatinib) in combination with Xeloda for the treatment of patients with advanced or metastatic HER2-positive breast cancer who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.